StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$94.23−2.10 (-2.18%)

Close on Nov 16, 2026Market cap $14.81BP/E 72.5Yield –

Kiniksa Pharmaceuticals International gross margin

Gross margin is gross profit as a percentage of revenue.

Kiniksa Pharmaceuticals International's gross margin for the twelve months ending Sep 30, 2026 was 90.2%. For fiscal 2025 it was 88.5%, against 85.6% the year before. The highest annual figure on record is 89.6% in fiscal 2022.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202588.5%+2.9
FY2024Dec 31, 202485.6%−2.0
FY2023Dec 31, 202387.6%−2.0
FY2022Dec 31, 202289.6%+13.2
FY2021Dec 31, 202176.4%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202690.3%+1.5
Q2 FY2026Jun 30, 202690.3%+2.2
Q1 FY2026Mar 31, 202690.3%+3.3
Q4 FY2025Dec 31, 202589.6%+4.2
Q3 FY2025Sep 30, 202588.8%+6.7
Q2 FY2025Jun 30, 202588.1%−0.5
Q1 FY2025Mar 31, 202587.0%+0.3
Q4 FY2024Dec 31, 202485.4%−3.1
Q3 FY2024Sep 30, 202482.1%−4.4
Q2 FY2024Jun 30, 202488.7%−0.6
Q1 FY2024Mar 31, 202486.7%+1.3
Q4 FY2023Dec 31, 202388.5%−0.6
Q3 FY2023Sep 30, 202386.4%−6.6
Q2 FY2023Jun 30, 202389.2%+7.9
Q1 FY2023Mar 31, 202385.4%+6.1
Q4 FY2022Dec 31, 202289.2%+12.0
Q3 FY2022Sep 30, 202293.0%+25.0
Q2 FY2022Jun 30, 202281.4%–
Q4 FY2021Dec 31, 202179.4%–
Q3 FY2021Sep 30, 202177.1%–
Q2 FY2021Jun 30, 202168.0%–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?